KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBITDA Margin (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed EBITDA Margin for 7 consecutive years, with 20147.47% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 2014942.0% year-over-year to 20147.47%, compared with a TTM value of 140.19% through Dec 2025, up 13771.0%, and an annual FY2025 reading of 6633.95%, down 663643.0% over the prior year.
  • EBITDA Margin was 20147.47% for Q4 2025 at Aurinia Pharmaceuticals, down from 43.16% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 43.16% in Q3 2025 and bottomed at 20147.47% in Q4 2025.
  • Average EBITDA Margin over 5 years is 1378.18%, with a median of 43.44% recorded in 2023.
  • The sharpest move saw EBITDA Margin soared 14557114bps in 2021, then plummeted -2014942bps in 2025.
  • Year by year, EBITDA Margin stood at 369.2% in 2021, then skyrocketed by 76bps to 89.96% in 2022, then surged by 34bps to 59.12% in 2023, then soared by 103bps to 1.95% in 2024, then tumbled by -1033663bps to 20147.47% in 2025.
  • Business Quant data shows EBITDA Margin for AUPH at 20147.47% in Q4 2025, 43.16% in Q3 2025, and 30.62% in Q2 2025.